Speaker illustration

Doctor Elisabetta Salvioni

Monzino Cardiology Centre, Milan (Italy)

Member of:

European Society of Cardiology
Heart Failure Association

A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

Event: Heart Failure 2024

Topic: Treatment

Session: ePosters in chronic heart failure - treatment 2

Thumbnail

Beta-blockers effects according to sex: does selectivity and dose equally matter?

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: Pharmacotherapy in heart failure

Thumbnail

Prognostic evaluation of heart failure in women: insight from the MECKI score database

Event: ESC Congress 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Nuggets from international and large registries

Thumbnail

How to calculate the anaerobic threshold to stratify HF prognosis: a comparison between absolute value, percentage of peakVO2 or percentage of predicted maxVO2 ina large multicenter cohort of HFrEF

Event: Heart Failure 2022

Topic: Epidemiology, Prognosis, Outcome

Session: Modern technologies in heart failure

Thumbnail

'You can leave your mask on': effects on cardiopulmonary parameters of different airway protection masks

Event: Heart Failure 2021

Topic: Exercise Testing

Session: ePoster session

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb